SYDNEY, AUSTRALIA and SAN DIEGO, CA–(Marketwire -02/06/12)- Benitec Biopharma (ASX: BLT.AX – News) and Medistem (Pinksheets: MEDS.PK – News) announced today the successful treatment of rheumatoid arthritis in preclinical models using Benitec Biopharma’s patented gene silencing technology applied to stem cell-derived immune system cells called dendritic cells. The studies, which were led by Dr. Wei-Ping Min of the University of Western Ontario, were published in the “Journal of Translational Medicine” on the 31st January 2012(1). Benitec Biopharma’s CEO Dr Peter French and Medistem’s scientist Dr Rosalia De Nochea Champion were co-authors on the paper.

Benitec Biopharma and Medistem Technologies Successfully Combined in Preclinical Stem Cell Therapy for Rheumatoid Arthritis